Overview

Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects

Status:
Completed

Trial end date:
2016-12-05

Target enrollment:

Participant gender:

Summary

This trial is looking to gain information about the safety and tolerability of an investigational treatment (SHP623) in healthy adult volunteers. This study will also collect pharmacokinetic data (how the body absorbs and breaks down the study drug).

Phase:

Phase 1

Details

Lead Sponsor:

Shire

Treatments:

Complement C1 Inactivator Proteins
Complement C1 Inhibitor Protein
Complement C1s